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1INTRODUCTION
Macular edema is an abnormal thickening of macula due to 
accumulation of fluid in extracellular spaces of the retina. It can occur 
due to circulatory disturbances and inflammatory conditions.
Cystoid macular edema is accumulation of fluid in cyst like 
spaces in macula evident on clinical examination, fundus fluorescein 
angiography or optical coherence tomography.
          Diabetic macular edema is a microvascular complication of 
diabetes mellitus. It is one of the leading causes of vision loss in 
patients with diabetic retinopathy. Laser photocoagulation has been 
the standard treatment of diabetic macular edema. But in cases of long 
standing macular edema fluid tends to accumulate in cyst like spaces 
i.e. cystoid macular edema which can cause permanent visual loss. It 
is usually refractory to laser photocoagulation treatment.
          Intravitreal Triamcinolone Acetonide has been recently used to 
treat diabetic cystoid macular edema in cases refractory to laser 
photocoagulation treatment.  It reduces microvascular leakage by its 
2anti-inflammatory effects thereby reducing macular edema. The usual 
dosage used is 4 mg in 0.05 ml. The major adverse effects of this 
treatment had been the formation of cataract in phakic patients and 
intraocular pressure elevation.
In this study we have compared the efficacy and safety of the 
usual 4mg dose vs 2mg dose.
3ANATOMY OF THE MACULA
Macula is an oval zone of central retina in the posterior pole 
within the temporal retinal vascular arcades approximately 5.5 mm in 
diameter with a yellow colouration. The yellow colour is due to 
presence of Xanthophyll pigments in the bipolar cells and ganglion 
cells of this area.
          Fovea is the central area of the macula with a thickness of 250 
microns, 1.85 mm in diameter and it corresponds to central 5 degrees 
of the visual field. It is located 4 mm temporal to the optic disc and 
0.8 mm below the horizontal meridian.
Foveola is at the center of the fovea where it is thinnest due to 
sole presence of cone photoreceptors. It is 0.35 mm in diameter with a 
thickness of 0.13 mm and corresponds to the central 1 degree of the 
visual field. It is the area of highest visual acuity due to presence of 
only the photorecptors with other layers being absent appearing 
deeper red than the surrounding area because of the visibility of the 
deeper rich choroidal circulation. Parafoveal region is 0.5 mm zone 
4around the fovea and perifovea is a 1.5 mm band surrounding the 
parafoveal region.
HISTOPATHOLOGY
Layers of Retina:
1 . Retinal Pigment Epithelium
2 . Layer of Rods And Cones
3 . External Limiting Membrane
4 . Outer Nuclear layer
5 . Outer Plexiform Layer
6 . Inner Nuclear Layer
7 . Inner Plexiform Layer
8 . Ganglion cell layer
9.   Nerve Fibre layer
10. Internal Limiting Membrane
5At the fovea only the following layers are present
1 .  Retinal Pigment Epithelium
2 .  Photoreceptors(Only Cones)
3 .  External Limiting Membrane
4 .  Outer Nuclear Layer
5 .  Inner fibres of photoreceptors(Henle’s Layer)
6 .  Internal Limiting Membrane
At the macula the ganglion cells are much more in number than 
elsewhere in the retina being arranged in several layers. 
          The outer plexiform layer is made up of arborisation of axons 
of rods and cones with bipolar cell dendrites. It also includes Muller’s 
fibres and horizontal cell processes. It has a reticular structure but as 
the macula is approached it takes a fibrous structure called Henle’s 
fibre layer. The fibres run vertically at first and then obliquely near 
the macula and finally parallel to the surface. This layer is thickest at 
macula but almost absent at the fovea. 
6          There is also progressive disappearance of the rods towards the 
fovea. At the fovea the layers of the retina are spared aside so that 
light will fall directly on to the cone photoreceptors. The retinal 
pigment epithelium and choriocapillaries are thicker at the macula. 
This is important since the macula has no blood vessels in the foveal 
avascular zone.
Each cone is connected to only one ganglion cell but upto 100 
rods can connect to a single ganglion cell. At the center of the fovea 
cone cells are located in a 50 micron diameter area and are separated 
from each other by relatively wide spaces of watery cytoplasm of 
Muller cells. The thinness of the basal lamina and the watery 
cytoplasm allow the light to pass though easily.
7Anatomic Peculiarities of Macula causing an exaggeratedresponse 
to pathological processes
Peculiar susceptibility of the macula to a number of pathological 
processes both local and generalized is called ‘exaggerated response’ 
of the macula. The causes for this are listed below.
1 . Vascular Supply
The arcade arrangement of the capillaries which arise as an end 
artery system, together with the central avascular zone make the fovea 
a ‘watershed’ area. Local impairment of metabolism, whether from 
disturbances in perfusion and accumulation of metabolites or from the 
effects of capillary damage, lead to extracellular fluid accumulation at 
a faster rate than that can be absorbed.
2 . Tissue Architecture
Muller’s cells processes run horizontally in the outer plexiform 
layer, hence the retina loses its compact nature and this laxityenables 
large quantities of extracellular fluid to be accumulated in the macular 
region leading to the formation of cystoid macular edema.
83 . Cellular Constituents
The ganglion cells have a high metabolic rate and their 
dysfunction due to any cause leads to rapid accumulation of tissue 
metabolites. Most metabolites have a vasodilator effect and this along 
with the underlying hypoxia can lead to cystoid macular edema.
4 . Internal Limiting Membrane
The vitreous is an excellent diffusing medium and the internal 
limiting membrane provides little additional interference to the 
diffusion of toxic substances arising from the iris, peripheral choroid 
and pars plana. These substances may traverse the vitreous and 
because of the thinness and adherence of the internal limiting 
membrane in the foveal region, may preferentially disturb the 
function of the cells which are highly concentrated around the foveal 
rim, and also affect the macular capillary permeability.
5 . Choroid and RPE
The macular choroid and RPE are also thepreferential sitesfor 
degenerativechanges which may be hereditary, toxic or 
arteriosclerotic. There is a predisposition for choroidal vascular 
9diseases with decompensation and hemorrhage in the central area 
which is thought to be because RPE in the fovea is very active 
metabolically and this hyperactivity with the special hemodynamic 
effects of the narrow choroidal capillaries may lead to increased 
susceptibility.
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DIABETIC CYSTOID MACULAR EDEMA
It is the most frequent cause of moderate visual impairment in 
patient with NPDR. This is best detected by slit lamp biomicroscopy 
with +60D, +78D, +90D or Macular contact le. Its incidence increases 
with the type of DM (more common in Type 2 DM), duration of DM, 
age of onset, use of insulin, uncontrolled DM, associated risk factors 
like hypertension, hyperlipidemia, anemia and nephropathy.
Pathogenesis of Diabetic Macular Edema
1 . Blood Retinal Barrier Breakdown
The most common pathway that results in diabetic macular 
edema is disruption of inner blood retinal barrier. It 
compartmentalizes the neurosensory retina from the vascular 
component of the eye. The inner blood retinal barrier is formed by 
tight junctional complexes between retinal vascular endothelium and 
the glial cells.
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The mechanism of the blood retinal barrier breakdown is 
multifactorial. It is secondary to changes in the tight junctions, 
pericyte loss, endothelial loss, retinal vascular endothelium and RPE 
cells, down regulation of glial cell derived neurotropic factor, retinal 
vessel dilation and vitreoretinal traction.
2 . Vasoactive factors
Sustained hyperglycemia affects several vasoactive factors such 
as VEGF, protein kinase c, heparin, angiotensin II, PEDF, 
metalloproteinases and biochemical pathways in diabetes, which may 
influence the development of structural and functional changes in 
diabetic retinopathy. Hypoxia and hyperglycemia upregulate VEGF 
production which in turn increase vasopermeability by activating 
PKC, hyperglycemia upregulate VEGF production in diabetic 
retinopathy which in turn increases vasopermeability by activating 
PKC, hyperglycemia increase PKC and angiotensin II both of which 
cause vasoconstriction ad worsening of hypoxia by their effect on 
endothelins.
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3. Vitreoretinal Interface
DME may be exacerbated due to persistent vitreomacular 
traction by residual cortical vitreous on the macula after PVD. 
Thickened and taut posterior hyaloid that may or may not be adherent 
to ILM, macular traction due to tractional proliferative membranes or 
loculation of cytokines in the premacular vitreous pocket lead to 
DME.
Clinical Features
1 . Thickening of macula
2 . Blurring of underlying choroid
3 . Loss of foveolar light reflex if foveola is involved
4 . Cystoid spaces
5 . Lipid exudation from leaking microaneurysms forming circinate 
retinopathy
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Diagnosis of DME
This is best detected by slit lamp biomicroscopy with +90 D, 
+78 D or Macular contact lens. Fundus fluorescein angiography is the 
standard method used to evaluate patients with DME that is sensitive 
for qualitative detection of fluid leakage. OCT aids in quantification 
of retinal thickening and for classification.
         OCT has its role in diagnosis and quantification of retinal 
thickening, macular volume, retinal morphology and vitreoretinal 
relationship in DME. It is also important in defining the indication of 
surgery, determining the prognosis and quantifying the response to 
therapy. The main pathology in DME is accumulation of fluid 
intraretinally. This is seen as reduced backscattering seen most 
commonly in the outer retinal layers.
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CLINICALLY SIGNIFICANT MACULAR
EDEMA (CSME)
1. Thickening of retina  <500 microns from the center of the 
macula
2. Hard exudates with retinal thickening of the adjacent retina 
located within 500 microns from the center of the macula
3. A zone of retinal thickening 1 disc area or larger in size located 
1 disc diameter from the center of the macula
FFA CLASSIFICATION OF MACULAR EDEMA
1 . Focal Maculopathy
Areas of focal leakage from microaneurysms and dilated 
capillary segments. These focal areas of retinal thickening are 
delineated from adjacent healthy retina by complete or partial ring of 
hard exudates. Focal edema show leakage in late phase.
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2. Diffuse Maculopathy
Breakdown of blood retinal barrier with leakage from 
microaneurysms and dilated capillary bed throughout posterior retina 
causes diffuse edema. 
It differs from focal edema by:
i) Diffuse edema is usually not associated with hard exudates
ii) Even when edema resolves spontaneously it does not leave 
hard exudates
iii) Cystoid spaces develop more commonly in DME. It is visible 
clinically, but seen better in late phase of FFA and OCT as 
hyper reflective septa
iv) Mostly bilaterally symmetrical
v) May disappear spontaneously at the same time in both eyes 
even without laser only to reappear spontaneously
3 . Ischemic Maculopathy
Ischemic type of lesion has the following features
- Enlargement of FAZ
16
- Irregularities of FAZ
- Capillary budding into FAZ
- Widening of intercapillary space and capillary 
drop out in the perifoveal area
4 . Mixed Maculopathy
A combination of focal maculopathy and diffuse maculopathy
OCT CLASSIFICATION OF MACULAR EDEMA
1 . Spongy Edema
It is the most common presentation. Cross sectional scans show 
swelling of the retina giving spongy appearance with increased retinal 
thickness. Back scattering seen from intra retinal fluid accumulation. 
It is confined mostly in outer retinal layers while inner retinal layer 
maintain their normal reflectivity.
2. Cystoid Edema
It is the second most common presentation which shoes 
intraretinal cystoid spaces. Involves variable depth of retina, has 
17
intervening space inbetween. Progress gradually to involve the whole 
of the retinal thickness.
3 . Serous Detachment
          It is seen as a hyporeflective area between neurosensory retina 
and RPE.
4 . Taut Posterior Hyaloid Membrane
          Taut thickened shiny glistening hypereflective membrane with 
striations on retina over the posterior pole with attachment to the disc 
and top of the elevated macular surface. Retinal thickness is greatly 
increased with intraretinal hyporeflective cyst like cavities. May also 
present as macular edema with foveal detachment.
5 . Vitreomacular Traction
          It is seen as a hyporeflective membrane extending from the 
vitreous to the macula. It causes detachment of fovea. It is an 
indication for pars plana vitrectomy. Laser will worsen macular 
edema.
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CLINICAL EVALUATION OF CYSTOID 
MACULAR EDEMA
1. Visual Acuity
Loss of vision mainly depends on the involvement of the 
macula.
2. Perimetry
Field charting by perimetry may reveal scotomas corresponding 
to areas of involvement in the fundus.
3. Colour vision
         The most common defect observed is blue yellow. In diabetes 
the sensitivity of blue cones are depressed. These facts are best 
detected by Farnsworth Munsell 100 hue test.
4 . Stereoscopic Indirect Ophthalmoscope
This technique is of special importance because it allows the 
examiner to integrate the view of the entire retina. This allows the 
19
examiner to form a clear understanding of the cause and forces 
involved in the various pathological features involving the retina.
5 . Slit Lamp Biomicroscopy
Since the biomicroscope is focused at about 95mm, the retina is 
not visible unless any of the below optical methods are used:
                1 . Goldmann Contact Lens – 3 mirror
                2 . Hruby Lens
                3 . 90 D, 78 D condensing Lens
         By combining these maneuvers, I is possible to see virtually the 
entire retina.
6 . Direct Ophthalmoscope
         Though the area of field observed is smaller, increased 
magnification obtained with this method allows detailed examination 
of the various details of thefundus.
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7 . Threshold Amsler Grid Testing
This rapid, sensitive and high yield means of assessing the 
central fields in patients with diabetic retinopathy.
8 . Photo Stress Test
After images and central scotomas persist even after a long time. 
This explains the prolonged readaptation time s in photo stress test in 
the affected eye.
9 . Electrophysiology
 Electroretinography – Early stages of diabetic 
retinopathy may reveal abnormalities of oscillatory 
potential in the ascending limb of the b wave. Delay in 
implicit time occurs as the macular edema progresses.
 Electrooculography – May reveal abnormal light to 
dark ratio(Arden’s Ratio)
 Visually Evoked responses – The macular disease with 
edema, the VER shows amplitude reduction depending 
on the reduced visual acuity with no change in latency.
21
10 . Fluorescein Angiography
         This is one of the mandatory investigations needed in macular 
edema for
i) Confirmation of diagnosis
ii) Documentation of the various lesions
iii) Deciding about the management
iv) Follow up
11. OCT
This investigation can also be used for diagnosis and follow up. 
It has the added advantage of being noninvasive. In addition 
parameters like the macular thickness can be quantified on subsequent 
visits, the macular edema patterns seen on OCT are as follows
i) Sponge like retina
      It is mostly confined to outer retinal layers due to 
backscattering from intraretinal fluid.
ii) Cystoid macular Edema
            Cystoid spaces confined to outer retina only. In long 
standing cases thy fuse to form large cyst.
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iii) Serous retinal detachment
            Hyporeflective space under fovea. It may disappear 
following laser.
iv) Tractional macular edema
            Foveovitreal traction causes detachment of fovea. It is 
an indication for pars plana vitrectomy to release traction. 
Laser will worsen macular edema in these cases.
v) Taut posterior hyaloid membrane
Cystoid spaces confined to outer retina mostly. In long 
standing cases they fuse to form large cyst.
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EVOLVING THERAPIES FOR CLINICALLY 
SIGIFICANT MACULAR EDEMA
LASER PHOTOCOAGULATION:
The goal of laser photocoagulation in DME is to limit vascular 
leakage through focal laser burns of leaking microaneurysms or grid 
laser burns in area of diffuse breakdown of blood retinal barrier.
Moderate vision loss was reduced by 50% in patients who 
received laser therapy in the ETDRS. Double frequency Nd:YAG 
laser(532nm) is the laser of choice in the management of DME.
          Treatment strategy given by ETDRS is to photocoagulate all 
leaking microaneurysms further than 500 microns from the center of 
macula and to place grid of 50-100 micron burns in areas of capillary 
leakage. Complications such as RPE atrophy, laser scars, subretinal 
fibrosis can lead to visual loss.
          The early Treatment for Diabetic retinopathy Study(ETDRS) 
established the indications and guidelines for laser treatment in DME. 
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Laser treatment is indicated for CSME which is defied by atleast one 
of the following:
 Thickening of the retina <500 microns from the center of the 
macula
 Hard exudates with thickening of the adjacent retina located 500 
microns from the center of the macula
 A zone of retinal thickening, 1 disc area or larger in size located 
1 disc diameter from the center of the macula
Intravitreal Corticosteroid:
The rationale for the use of corticosteroids in CSME is it 
stabilizes blood retinal barrier It inhibits VEGF and other cytokines 
growth factors that regulate endothelial tight junctions. They also 
reduce the synthesis of prostaglandins and leukotrienes, two potent 
inflammatory mediators. The resultant anti-inflammatory effect 
contributed to the reduction of macular edema. Increased diffusion by 
modulation of calcium channels could also account for the efficacy of 
corticosteroids. IVTA reduces retinal thickening on OCT and 
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improves vision in as substantial number of patients, Patients with 
cystoid macular edema respond better.
However duration of effect varies and visual decline are often 
observed 4 to 6 months after injection. Repeated therapy is often 
limited by side effects. Intraocular pressure elevation occurs in about 
one third of patients. Acceleration of cataract formation, 
endophthalmitis retinal detachment are other complications.
Intravitreal Anti-VEGF agents
Anti-EGF agents work to restore the normal permeability of 
blood retinal barrier. VEGF increases vascular permeability by 
relaxing endothelial junction. Inhibition of VEGF blocks this effect to 
some extent.
Ranibizumab(Lucentis) is a humanized antigen binding 
fragment(Fab) of a second generation, recombinant monoclonal 
antibody against VEGF. It has high specificity and affinity for all 
soluble human isoforms of VEGF.
Bevacizumab(Avastin) is a full length humanized monoclonal 
antibody for treatment of metastatic colorectal cancer. Intravitreal 
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formulation was first used off label for the treatment of age related 
macular degeneration. In cases of diffuse edema that failed other 
modalities of treatments, intravitreal injection of Bevacizumab was 
associated with improved injection and decreased retinal thickness 12 
weeks after the first injection. 
Pegatanibsodium(Macugen) is an anti VEGF aptamer blocking the 
effect of VEGF-165 isoform alone.
Protein Kinase C Inhibitor
Protein kinase C is upregulated in hyperglycemia in vascular 
endothelial cells of multiple tissues. Oral administration of 
Ruboxistaurin 32mg/day over a period of 36 months have 
demonstrated the efficacy in prevention of sustained moderate vision 
loss in NPDR by reducing the macular edema within 100 microns 
from the center of the macula and the need for initial laser treatment.
27
PART II
28
AIM OF THE STUDY
To Prospectively Compare the Efficacy of 4mg Vs 2mg 
Intravitreal Triamcinolone Acetonide Injection for Diabetic Cystoid 
Macular Edema
PRIMARY OBJECTIVE
To determine the dose with superior visual outcome 
SECONDARY OBJECTIVE
To determine the dose with less complications with equivocal 
clinical benefits
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INCLUSION CREITERIA
1. Diabetic Retinopathy patients  with clinically significant 
macular  edema
2. Visual acuity  <6/12
3. Cystoid(Flower Petal) pattern shown by Fundus Fluorescein
Angiography
EXCLUSION CRITERIA
1 . Macular edema due to other causes
2 . One eyed patients
3 . Intraocular surgery within 3 months
4 . Previous treatment with prp, anti-vegf or intravitreal steroids
5 . Patients with high intraocular pressure
6 . Patients with history of corticosteroid-responsive intraocular
pressure (IOP) rise
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MATERIALS AND METHODS
This prospective interventional study was conducted in the 
department of Uvea-Retia services, RIOGOH, Chennai for a duration 
of 6 months. 50 patients were selected who were referred to Uvea-
Retina clinic with provisional diagnosis of Diabetic Cystoid Macula 
Edema  based upon the inclusion criteria.
          All the patients were taken brief history and subjected to 
detailed systemic and ocular examination which includes visual acuity 
using Snellen’s chart, intraocular pressure evaluation using Goldmann 
applanation tonometry, slit lamp biomicroscopy examination with 
90D, binocular indirect ophthalmoscopy and  detailed fundus 
drawings were done and fundus photographs were also taken for 
documentation.
          Fundus fluorescein angiography was done to determine the type 
of macular edema. Central Macular Thickness was assessed with 
optical coherence tomography to quantify macular edema.
A commercially available Triamcinolone Acetonide was 
prepared in two concentrations of 4mg/0.1ml and 2mg/0.1ml  
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andplaced in a tuberculin syringe using aseptic precautions. Patients 
were randomly allocated into two groups (Group I & Group II). The 
first group(Group I)containing 25 patients received 4mg of 
intravitreal TA and the second group(Group II) containing the 
remaining 25 patients received 2mg of intravitreal TA. 
The procedure was performed in an operation theatre under 
sterile conditions. After the eye had been prepared in a standard 
fashion using 5% povidone iodine and topical antibiotics 
Triamcinolone was injected intravitreally via the pars plana. After the 
injection intraocular pressure and central retinal artery perfusion were 
checked and patients were instructed to administer topical antibiotics 
for 3 days. Patients were called 2 to 3 days after injection and were 
reexamined within 1 week.
Patients are reevaluated at 4, 12 and 24 weeks.On each follow 
up visit, the amount of macular edema, visual acuity andintraocular 
pressure are evaluated. Complications if any were treated 
accordingly.
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Intravitreal Injections – Procedure Guidelines:
Injection procedure guidelines include consideration of 
preexisting conditions such as active external infection, eyelid 
abnormalities, povidone iodine, lid scrubs, preinjection topical 
antibiotics, lid speculum, drape, gloves, topical anesthesia and 
postinjection topical antibiotics.
          In general the risk of endophthalmitis following intravitreal 
injection is estimated to be approximately <0.1%
Guidelines for Intravitreal Injection:
1. Povidone iodine for ocular surface, eyelid and lashes
2. Use of speculum and avoid contamination of the needle with eye 
lid margin
3. Avoid extensive massage of the eyelids either pre or post 
injection
4. Dilate pupil
5. Adequate use of topical anesthetics
6. Avoid prophylactic or post injection paracentesis
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7. IOP to be checked following injection
8. Detailed fundoscopic examination should be performed 
following injection to confirm central retinal artery perfusion 
and intraocular location of the drug
Guidelines for Follow Up:
Patients were followed up on the immediate day following 
intravitreal injection. They were followed up every week for 1 month, 
then every 2 weeks subsequently. Patients were instructed to contact 
ophthalmologist if there is ocular redness or discomfort or decreased 
vision compared to that present right after the injection procedure.
Main Outcome Measures:
 Best Corrected Visual Acuity(Snellen’s Chart)
 Central Macular Thickness by OCT
 Intraocular Pressure by Goldmann applanation tonometry
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OBSERVATION AND RESULTS
Age Distribution
Total no. of Patients – 50
Table – 1
Age Distribution No. of Patients Percentage
< 40 yrs 2 4
40 – 60 yrs 27 54
60 – 80 yrs 21 42
Most of the patients in our study were in the age group 40 – 60 
yrs(54%). The oldest patient was 72 years of age while the youngest 
was 40 years.
AGE DISTRIBUTION
< 40 YRS
40 - 60 YRS
60 - 80 YRS
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Age Distribution in Group I
Total no. of patients – 25
Table – 2
Age Distribution No. of Patients Percentage
< 40 yrs 1 4
40 – 60 yrs 13 52
60 – 80 yrs 11 44
Most of the patients in Group I were in the age group of 40 – 60 
yrs((54%). The oldest patient was 71 yrs of age while the youngest 
was 40 yrs of age.
Age Distribution in Group I
< 40 yrs
40 - 60 yrs
60 - 80 yrs
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Age Distribution in Group II
Total No. of Patients – 25
Table – 3
Age Distribution No. Of Patients Percentage
<40 yrs 1 4
40 – 60 yrs 14 56
60 – 80 yrs 10 40
Most of the patients in Group II were in the age group of 40 – 60 
yrs(56%). The oldest patient was 72 yrs of age while the youngest 
was 40 yrs of age.
Age Distribution in Group II
< 40 yrs
40 - 60 yrs
60 -80 yrs
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Sex Distribution
Table – 4
Sex No. of Patients Percentage
Male 24 48
Female 26 52
Sex distribution was almost equal, females comprising 52% and 
males comprising 48% of the total.
Sex Distribution
Male
Female
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Sex Distribution in Group I
Table – 5
Sex No. of Patients Percentage
Male 9 36
Female 16 64
Most of the patients in Group I were females comprising of 64% of 
the total.
Sex Distribution in Group I
Male
Female
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Sex Distribution in Group II
Table – 6
Sex No. of Patients Percentage
Male 15 60
Female 10 40
Most of the patients in Group II were males comprising of 60% of the 
total.
Sex Distribution in Group II
Male
Female
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Pre-Treatment Visual Acuity
Table – 7
Visual Acuity No. of Patients Percentage
< 3/60 3 6
3/60 – 6/60 31 62
6/60 – 6/24 16 32
>6/24 Nil -
Pre-Treatment Visual Acuity in Group I
Table – 8
Visual Acuity No. of Patients Percentage
< 3/60 3 12
3/60 – 6/60 14 56
6/60 – 6/24 8 32
>6/24 Nil -
Pre- Treatment Visual Acuity in Group II
Table – 9
Visual Acuity No. of Patients Percentage
< 3/60 1 4
3/60 – 6/60 16 64
6/60 – 6/24 8 32
>6/24 Nil -
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Post-Treatment Visual Acuity in Group I 
At 4 Weeks
Table – 10
Visual Acuity No. of Patients Percentage
< 3/60 3 12
3/60 – 6/60 12 48
6/60 – 6/24 9 36
>6/24 1 4
Post-Treatment Visual Acuity in Group I 
At 12 Weeks
Table - 11
Visual Acuity No. of Patients Percentage
<3/60 2 8
3/60 – 6/60 8 32
6/60 – 6/24 5 20
>6/24 10 40
Post-Treatment Visual Acuity in Group I 
At 24 Weeks
Table – 12
Visual Acuity No. of Patients Percentage
<3/60 2 8
3/60 – 6/60 8 32
6/60 – 6/24 8 32
>6/24 7 28
Comparison between Pre and Post 
Acuity in Group I Patients
There was a distinct improvement in visual acuity in Group I patients 
treated with 4mg Triamcinolone acetonide at 8 weeks and at 12 
weeks. Though there was slight decrease in visual acuity in some 
patients at 16 weeks post treatment.
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Post-Treatment Visual Acuity in Group II 
at 4 Weeks
Table-13
Visual Acuity No. of Patients Percentage
< 3/60 1 4
3/60 – 6/60 16 64
6/60 – 6/24 8 32
>6/24 Nil -
Post-Treatment Visual Acuity in Group II 
at 12 Weeks
Table-14
Visual Acuity No. of Patients Percentage
< 3/60 Nil -
3/60 – 6/60 9 36
6/60 – 6/24 15 60
>6/24 1 4
Post-Treatment Visual Acuity in Group II 
at 24 Weeks
Table-15
Visual Acuity No. of Patients Percentage
< 3/60 Nil -
3/60 – 6/60 17 68
6/60 – 6/24 8 32
>6/24 Nil Nil
Comparison between Pre and Post Tr
Visual Ac
In Group II patients treated with 2mg T
substantial improvement in visual acuity was noted at 8 weeks. 
Though there was some improvement noted at 12 weeks
in several patients at 16 weeks.
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Pre-Treatment Macular Thickness 
in Group I Patients
Table-16
Macular Thickness No. of Cases Percentage
200-400 microns 9 36
400-600 microns 7 28
600-800 microns 5 20
>800 microns 4 16
Pre-Treatment Macular Thickness 
in Group IIPatients
Table-17
Macular Thickness No. of Cases Percentage
200-400 microns 10 40
400-600 microns 7 28
600-800 microns 5 20
>800 microns 3 12
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Post-Treatment Macular Thickness 
in Group I Patients at 12 weeks
Table-18
Macular Thickness No. of Patients Percentage
200-400 microns 14 56
400-600 microns 11 44
600-800 microns - -
>800 microns - -
Post-Treatment Macular Thickness 
in Group I Patients at 24 weeks
Table-19
Macular Thickness No. of Patients Percentage
200-400 microns 18 72
400-600 microns 7 28
600-800 microns - -
>800 microns - -
Comparison of Pre and Post Treatment Macular 
Thickness in Group I Patients
In Group I patients treated with 4 mg Triamcinolone acetonide central 
macular thickness decreased substantially by 12 weeks and at 24 
weeks in many of the patients.
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Post-Treatment Macular Thickness 
in Group II Patients at 12 weeks
Table-20
Macular Thickness No. of Patients Percentage
200-400 microns 9 36
400-600 microns 13 52
600-800 microns 3 12
>800 microns - -
Post-Treatment Macular Thickness 
in Group II Patients at 24 weeks
Table-21
Macular Thickness No. of Patients Percentage
200-400 microns 8 32
400-600 microns 14 56
600-800 microns 3 12
>800 microns - -
Comparison of Pre and Post Treatment Ma
Thickness in Group II Patients
In Group II Patients treated with 2 mg Triamcinolone 
reduction in central macular thickness was less appreciable compared 
to the Group I patients at 4 weeks & 12 weeks and the thickness 
increased at 24 weeks in some of the patients
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Pre-Treatment Intraocular Pressure 
in Group I Patients
Table-22
Intraocular Pressure No. of Patients Percentage
10-12 mm HG 5 20
13-14 mm Hg 5 20
15-16 mm HG 10 40
17-18 mm HG 5 20
19-20 mm HG - -
>20 mm HG - -
Pre-Treatment Intraocular Pressure 
in Group II Patients
Table-23
Intraocular Pressure No. of Patients Percentage
10-12 mm HG 3 12
13-14 mm Hg 7 28
15-16 mm HG 10 40
17-18 mm HG 5 20
19-20 mm HG - -
>20 mm HG - -
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Post-Treatment Intraocular Pressure 
in Group I Patients at 4 weeks
Table-24
Intraocular Pressure No. of Patients Percentage
10-12 mm HG 2 8
13-14 mm Hg 5 20
15-16 mm HG 11 44
17-18 mm HG 3 12
19-20 mm HG 2 8
>20 mm HG 2 8
Post-Treatment Intraocular Pressure 
in Group I Patients at 12 weeks
Table-25
Intraocular Pressure No. of Patients Percentage
10-12 mm HG 1 4
13-14 mm Hg 6 24
15-16 mm HG 6 24
17-18 mm HG 9 36
19-20 mm HG 3 12
>20 mm HG - -
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Post-Treatment Intraocular Pressure 
in Group I Patients at 24 weeks
Table-26
Intraocular Pressure No. of Patients Percentage
10-12 mm HG 2 8
13-14 mm Hg 3 12
15-16 mm HG 11 44
17-18 mm HG 9 36
19-20 mm HG - -
>20 mm HG - -
Comparison of Pre an Post Treatment Intraocular 
Pressure in Group I Patients
Mild elevation of intraocular pressure was noted in some of the 
patients in  group II at 4 weeks and 12 weeks, 
normalized in most of them by 24 weeks.
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Post-Treatment Intraocular Pressure 
in Group II Patients at 4weeks
Table-27
Intraocular Pressure No. of Patients Percentage
10-12 mm HG 3 12
13-14 mm Hg 6 24
15-16 mm HG 11 44
17-18 mm HG 4 16
19-20 mm HG 1 4
>20 mm HG - -
Post-Treatment Intraocular Pressure 
in Group II Patients at 12 weeks
Table-28
Intraocular Pressure No. of Patients Percentage
10-12 mm HG 3 12
13-14 mm Hg 5 20
15-16 mm HG 10 40
17-18 mm HG 7 28
19-20 mm HG - -
>20 mm HG - -
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Post-Treatment Intraocular Pressure 
in Group II Patients at 24 weeks
Table-29
Intraocular Pressure No. of Patients Percentage
10-12 mm HG 2 8
13-14 mm Hg 6 24
15-16 mm HG 12 48
17-18 mm HG 5 20
19-20 mm HG - -
>20 mm HG - -
Comparison of Pre and Post Treatment Intraocular 
Pressure in Group II Patients
All the patients in this group maintained their intraocular pressure at 
their pretreatment levels, though mild elevation was noted in few 
patients at 4 weeks which normalized
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at 12 weeks and 24 weeks.
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Comparison between Pre and Post Treatment 
Macular OCT scans
Case – 1
Pre-injection OCT shows cystoid spaces intraretinally with serous 
macular detachment. Central macular thickness is 492 microns. 24 
weeks post-injection repeat OCT shows reduction in the cystoid 
spaces with macular thickness reduced to 184 microns.
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CASE – 2
Pre-injection : Multiple cystoid spaces with macular thickening
24 weeks Post-injection :Obliteration of cystoid spaces with normal 
foveal contour and central macular thickness
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DISCUSSION
The administration of intravitreal Triamcinolone is appealing for 
a number of reasons. In a country like India with a significant number 
of diabetics, visual morbidity due to diabetic macular edema is high. 
As of current practice, laser treatment as advocated by the ETDRS 
study remains the standard therapy for diabetic macular edema. 
However cystoid macular edema in long standing cases which is 
refractory to laser treatment can be considered for treatment with 
pharmacological agents like intravitreal triamcinolone acetonide or 
anti VEGF agents. There have been RCTs which have demonstrated 
that intravitreal triamcinolone alone can provide visual and 
anatomical benefits for upto 2 years (Gillies et al, Ophthalmology 
2006). Anti VEGF agents though a promising mode of therapy, 
remains a costly affair in a developing economy like India. In this 
scenario, therapy with intravitreal corticosteroids can be considered 
for individual patients after risk-benefit evaluation.
         In previous studies of the effects of intravitreal triamcinolone 
acetonide on diabetic macular edema, various doses of TA were used. 
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The most frequent is 4mg, chosen empirically, because it constitutes 
0.1ml of the commercially available 40mg TA formula. However ths 
treatment is associated with complications of intraocular pressure 
elevation and cataractous lens changes in some patients.
We studied here the efficacy and safety of 4mg vs 2mg 
intravitreal triamcinolone acetonide for cystoid macular edema to see 
whether reducing the dosage level reduces the complication rate and 
at the same time providing equivocal clinical benefits.
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SUMMARY
 This is a six month prospective,non-randomized clinical study to 
compare the efficacy and safety of 4 mg Vs 2mg intravitreal 
triamcinolone acetonide injection in the treatment of diabetic 
cystoid macular edema.
 The main aim was to evaluate the dose with superior visual 
outcome assessed by improvement in visual acuity and decrease 
in macular thickness and to determine  the dose with fewer 
complications with equivocal clinical benefits assessed by 
recording changes in intraocular pressure.
 50 patients with diabetic cystoid macular edema were enrolled 
for this study ad they were divided into two groups of 25 each. 
The first group received 4 mg intravitreal triamcinolone actinide 
injection and the second group received 2 mg intravitreal 
triamcinolone acetonide.
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 Most of the patients in our study were in the age group 40 – 60 
yrs(54%). The oldest patient was 72 years of age while the 
youngest was 40 years.Most of the patients in Group I were in 
the age group of 40 – 60 yrs((54%). The oldest patient was 71 
yrs of age while the youngest was 40 yrs of age.Most of the 
patients in Group II were I the age group of 40 – 60 yrs(56%). 
The oldest patient was 72 yrs of age while the youngest was 40 
yrs of age.
 Sex distribution was almost equal, females comprising 52% and 
males comprising 48% of the total. Most of the patients in 
Group I were females comprising of 64% of the total. Most of 
the patients in Group II were males comprising of 60% of the 
total.
Visual Acuity:
 There was a distinct improvement in visual acuity in Group I 
patients treated with 4mg Triamcinolone acetonide at 8 weeks 
and at 12 weeks. Though there was slight decrease in visual 
acuity in some patients at 16 weeks post treatment.
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 In Group II patients treated with 2mg Triamcinolone Acetonide,
no substantial improvement in visual acuity was noted at 8 
weeks. Though there was some improvement noted at 12 weeks,
it declined in several patients at 16 weeks.
Macular Thickness:
 In Group I patients treated with 4 mg Triamcinolone acetonide 
central macular thickness decreased substantially by 12 weeks 
and at 24 weeks in many of the patients.
 In Group II Patients treated with 2 mg Triamcinolone 
Acetonide, the reduction in central macular thickness was less 
appreciable compared to the Group I patients at 4 weeks & 12 
weeks and the thickness increased at 24 weeks in some of the 
patients.
Intraocular Pressure Measurements:
 Mild elevation of intraocular pressure was noted in some of the 
patients in this group at 4 weeks and 12 weeks, though it was 
normalized in most of them by 24 weeks.   
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 Mild elevation of intraocular pressure was noted in some of the 
patients in  group II at 4 weeks and 12 weeks, though it was 
normalized in most of them by 24 weeks.
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CONCLUSIONS
 Visual improvement is noted with both 4 mg and 2 mg 
Intravitreal Triamcinolone Acetonide though it is more 
pronounced and sustained with 4 mg dosage compared with 2 
mg dosage
 Both 4 mg and 2 mg Intravitreal Triamcinolone Acetonide are 
well tolerated over 6 month period with significant safety. But 4 
mg dosage is associated with mild elevation of intraocular 
pressure in some patients unlike 2 mg dosage which appears to 
be more safer
Nevertheless, this is a small interventional study with no 
comparison arm to quantify the actual magnitude of efficacy and 
safety of these treatment modalities.
This would have to be studied subsequently in larger studies and 
also need to be compared with other latest treatment modalities for 
efficacy and safety.
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PART III
67
PROFORMA
PATIENT INFORMATION:
Name                  :
Age                     :
Sex                      :
Occupation         :
OP No.                 :
Address               :
Phone No.           :
CHIEF COMPLAINTS
 Defective Vision
 Distorted Vision
 Pain In The Eye
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PAST HISTORY
 Diabetes
- No. of years
- Type I/II
- On oral hypoglycemic
- Whether blood sugar under control
- Associated with NVG
- PRP given/not
          If given – no of sittings
 Hypertension
- No of years
- Associated with ischemic heart disease/ 
hyperlipidemia / cerebrovascular accident
 Ocular surgery
- Date of surgery
- Time since defective vision
- Type and duration of topical medications used
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SYSTMIC EXAMINATION
PR :
                  BP :
                  RBS :
                  Urine Albumin& Sugar :
OCULAR EXAMINATION
RE LE   
Visual Acuity        -
Tension(APT)         -
Conjunctiva              -
Cornea                      -
Iris                               -
Ant. Chamber            -
Lens                         -
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Slit Lamp Ex         -
Fields                     -
Colour Vision    -
Fundus by 90D         -
Fundus by IDO -
Fundus Fluorescein Angiography   : Type of Leak
Optical Coherence Tomography     : Macular Thickness
TREATMENT HISTORY
Under aseptic precautions, under topical anesthesia, Inj. 
Triamcinolone acetonide 2mg or 4 mg is injected intravitreally
Date –
OUTCOME OF TREATMENT
